PillRx only · Injection · Intravenous
Meropenem
Meropenem
9 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US20 NDCs
9 active makers
9 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
ATC—
RxCUI (US)—
US makers9 labelers
Packages30
DEA / ScheduleNone
US acquisition costNADAC · per unit
Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$5.163
Latest avg · Jun 17, 2026
-9%
Since Dec 17, 2025
9
Active US suppliers
43%
Top-2 supplier share*
Who makes it9 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| BROOKS STERISCIENCE LIMITED | unknown | 7 | SUPPLYING |
| Armas Pharmaceuticals Inc. | unknown | 6 | SUPPLYING |
| Sandoz Inc | unknown | 4 | SUPPLYING |
| Civica, Inc. | unknown | 4 | SUPPLYING |
| Qilu Antibiotics Pharmaceutical Co., Ltd. | unknown | 2 | SUPPLYING |
| Hikma Pharmaceuticals USA Inc. | unknown | 2 | SUPPLYING |
| Savior Lifetec Corporation | unknown | 2 | SUPPLYING |
| Gland Pharma Limited | unknown | 2 | SUPPLYING |
| Mylan Institutional LLC | unknown | 1 | SUPPLYING |
Regulatory & supply events
No recalls, shortages, or registration changes on record for this drug concept.